Nytt Handlingsprogram for maligne blodsykdommer er nå ferdig utarbeidet og innsendt til Helsedirektoratet og vil være tilgjengelig på Helsedirektoratets hjemmesider i løpet av 2 til 3 måneder. Vi  ønsker imidlertid å gjøre dette tilgjengelig for medlemmene tidligere og legger derfor ut de innsendte kapitlene på NSH hjemmesider. Siden Helsedirektoratet legger inn referanser i dokumentene for oss er dette kun angitt som kommentarer i noen av dokumentene. Siden siste revisjon er kapittelet om akutt myelogen leukemi totalrevidert.




KLL og lymfoproliferative neoplasier

Andre lymfoproliferative neoplasier




Cold agglutinin disease (CAD) is an uncommon autoimmune haemolytic anaemia in which a well‐defined, clonal low‐grade lymphoproliferative disorder of the bone marrow results in erythrocyte destruction mediated by the classical complement pathway. The pathogenesis, clinical features and diagnostic criteria are reviewed. Although anaemia is mild in some patients, approximately one‐third of untreated patients have a haemoglobin level of ≤80 g/l, and about 50% have been considered transfusion dependent for shorter or longer periods. Therapy has improved greatly during the last 15 years. Mild disease can be managed by avoidance of cold and adequate precautions in specific situations, without drug therapy. Corticosteroids should not be used to treat CAD. Patients requiring pharmacological therapy should be considered for prospective trials. Outside clinical studies, the rituximab‐bendamustine combination or rituximab monotherapy is recommended in the first line, depending on individual patient characteristics. Second‐line options are rituximab‐fludarabine in fit patients or, although less strongly documented, a bortezomib‐based regimen. Therapies targeting the classical complement pathway are promising, and the complement C1s inhibitor, BIVV009, has shown favourable results in preliminary studies.


Welcome to the 51th Nordic Coagulation Meeting
Stockholm 6-8 of September 2018

Program og påmelding

• In venous thromboembolism (VTE), it is uncertain if enoxaparin should be given twice or once daily.

• We compared the 15- and 30-day outcomes in VTE patients on enoxaparin twice vs. once daily.

• Patients on enoxaparin once daily had fewer major bleeds and deaths than those on twice daily.

• The rate of VTE recurrences was similar in both subgroups.

Artikkel - JTH

Siste nyheter

Ingen aktiviteter funnet